Mumbai, June 3 (Udaipur Kiran): Mankind Pharma is currently trading at Rs. 2310.35, up by 11.85 points or 0.52% from its previous closing of Rs. 2298.50 on the BSE.
The scrip opened at Rs. 2339.60 and has touched a high and low of Rs. 2339.60 and Rs. 2287.00 respectively. So far 4148 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 2726.75 on 15-Jul-2025 and a 52 week low of Rs. 1909.90 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 2,640.00 and Rs. 2,239.20 respectively. The current market cap of the company is Rs. 94983.57 crore.
The promoters holding in the company stood at 72.66%, while Institutions and Non-Institutions held 24.66% and 2.68% respectively.
Mankind Pharma’s wholly owned subsidiary (WOS) — Mankind Lifesciences (MLS) has acquired the remaining 10% stake of Upakarma Ayurveda (Upakarma) from Kaushcorp Media LLP through a share purchase agreement (SPA) for Rs 75 lakh (payable in two tranches as per SPA) on June 2, 2026. MLS is already holding 90% stake in Upakarma.
This acquisition will enable the company to achieve better operational efficiencies through streamlined processes. Consequent to this acquisition, Upakarma has become a WOS of MLS and a step-down WOS of the company.
Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
